131 related articles for article (PubMed ID: 23531737)
1. Prognostic importance of 18F-FDG uptake pattern of hepatocellular cancer patients who received SIRT.
Kucuk ON; Soydal C; Araz M; Bilgic S; Ibis E
Clin Nucl Med; 2013 Jul; 38(7):e283-9. PubMed ID: 23531737
[TBL] [Abstract][Full Text] [Related]
2. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer.
Fendler WP; Philippe Tiega DB; Ilhan H; Paprottka PM; Heinemann V; Jakobs TF; Bartenstein P; Hacker M; Haug AR
J Nucl Med; 2013 Aug; 54(8):1202-8. PubMed ID: 23729697
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of quantitative parameters of 18F-FDG PET/CT in the evaluation of response to internal radiation therapy with yttrium-90 in patients with liver metastases of colorectal cancer.
Soydal C; Kucuk ON; Gecim EI; Bilgic S; Elhan AH
Nucl Med Commun; 2013 May; 34(5):501-6. PubMed ID: 23478586
[TBL] [Abstract][Full Text] [Related]
4.
Jreige M; Mitsakis P; Van Der Gucht A; Pomoni A; Silva-Monteiro M; Gnesin S; Boubaker A; Nicod-Lalonde M; Duran R; Prior JO; Denys A; Schaefer N
Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1215-1222. PubMed ID: 28233086
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the response to selective internal radiation therapy in patients with hepatocellular cancer according to pretreatment (99m)Tc-MAA uptake.
Kucuk ON; Soydal C; Araz M; Ozkan E; Aras G
Clin Nucl Med; 2013 Apr; 38(4):252-5. PubMed ID: 23429390
[TBL] [Abstract][Full Text] [Related]
6. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer.
Haug AR; Tiega Donfack BP; Trumm C; Zech CJ; Michl M; Laubender RP; Uebleis C; Bartenstein P; Heinemann V; Hacker M
J Nucl Med; 2012 Mar; 53(3):371-7. PubMed ID: 22331219
[TBL] [Abstract][Full Text] [Related]
7. Survival in patients with hepatocellular carcinoma treated with 90Y-microsphere radioembolization. Prediction by 18F-FDG PET.
Sabet A; Ahmadzadehfar H; Bruhman J; Sabet A; Meyer C; Wasmuth JC; Pieper CC; Biersack HJ; Ezziddin S
Nuklearmedizin; 2014; 53(2):39-45. PubMed ID: 24777354
[TBL] [Abstract][Full Text] [Related]
8. Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for unresectable primary and metastatic liver tumors.
Kucuk ON; Soydal C; Lacin S; Ozkan E; Bilgic S
World J Surg Oncol; 2011 Aug; 9():86. PubMed ID: 21819613
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization.
Piduru SM; Schuster DM; Barron BJ; Dhanasekaran R; Lawson DH; Kim HS
J Vasc Interv Radiol; 2012 Jul; 23(7):943-8. PubMed ID: 22609292
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors for prediction of survival of hepatocellular cancer patients after selective internal radiation therapy.
Soydal C; Keskin O; Kucuk ON; Ozkan E; Bilgic S; Idilman R; Kir MK
Ann Nucl Med; 2015 Jun; 29(5):426-30. PubMed ID: 25783289
[TBL] [Abstract][Full Text] [Related]
11. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI.
Wong CY; Salem R; Raman S; Gates VL; Dworkin HJ
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):815-20. PubMed ID: 12029557
[TBL] [Abstract][Full Text] [Related]
12. Comparison of PERCIST and RECIST criteria for evaluation of therapy response after yttrium-90 microsphere therapy in patients with hepatocellular carcinoma and those with metastatic colorectal carcinoma.
Sager S; Akgün E; Uslu-Beşli L; Asa S; Akovali B; Sahin O; Yeyin N; Demir M; Abuqbeitah M; Gülsen F; Sayman H; Sönmezoglu K
Nucl Med Commun; 2019 May; 40(5):461-468. PubMed ID: 30896544
[TBL] [Abstract][Full Text] [Related]
13. Initial outcome after selective intraarterial radionuclide therapy with yttrium-90 microspheres as salvage therapy for unresectable metastatic liver disease.
Turkmen C; Ucar A; Poyanli A; Vatankulu B; Ozkan G; Basaran M; Serin K; Sanli Y; Adalet I
Cancer Biother Radiopharm; 2013 Sep; 28(7):534-40. PubMed ID: 23647219
[TBL] [Abstract][Full Text] [Related]
14. FDG PET/CT as a prognostic test after 90Y radioembolization in patients with metastatic hepatic disease.
Zalom M; Yu R; Friedman M; Bresee C; Waxman A
Clin Nucl Med; 2012 Sep; 37(9):862-5. PubMed ID: 22889775
[TBL] [Abstract][Full Text] [Related]
15. FDG PET for monitoring response to local and locoregional therapy in HCC and liver metastases.
Dierckx R; Maes A; Peeters M; Van De Wiele C
Q J Nucl Med Mol Imaging; 2009 Jun; 53(3):336-42. PubMed ID: 19521313
[TBL] [Abstract][Full Text] [Related]
16. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma.
Trojan J; Schroeder O; Raedle J; Baum RP; Herrmann G; Jacobi V; Zeuzem S
Am J Gastroenterol; 1999 Nov; 94(11):3314-9. PubMed ID: 10566736
[TBL] [Abstract][Full Text] [Related]
17. Prognostic implication of (18)F FDG-PET in patients with extrahepatic metastatic hepatocellular carcinoma undergoing systemic treatment, a retrospective cohort study.
Shin DY; Han SW; Oh DY; Im SA; Kim TY; Bang YJ
Cancer Chemother Pharmacol; 2011 Jul; 68(1):165-75. PubMed ID: 20872146
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of maximum standardized uptake value (SUVmax) on 18F-FDG PET/CT in patients with locally advanced or metastatic pancreatic cancer.
Moon SY; Joo KR; So YR; Lim JU; Cha JM; Shin HP; Yang YJ
Clin Nucl Med; 2013 Oct; 38(10):778-83. PubMed ID: 24107806
[TBL] [Abstract][Full Text] [Related]
19. Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy: Safety and Efficacy Cohort Study.
Xing M; Prajapati HJ; Dhanasekaran R; Lawson DH; Kokabi N; Eaton BR; Kim HS
Am J Clin Oncol; 2017 Feb; 40(1):27-34. PubMed ID: 25089529
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib.
Lee JH; Park JY; Kim DY; Ahn SH; Han KH; Seo HJ; Lee JD; Choi HJ
Liver Int; 2011 Sep; 31(8):1144-9. PubMed ID: 21745288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
